State Street Corp Has $395.31 Million Holdings in Elanco Animal Health Incorporated $ELAN

Key Points

• State Street increased its Elanco Animal Health stake by 4.7% in the second quarter to 16.06 million shares valued at approximately $395.3 million. Institutional investors collectively own 97.48% of the company.
• Analysts maintain a generally positive outlook, with an average rating of “Moderate Buy” and a consensus price target of $29.70. UBS, KeyCorp and TD Cowen recently raised their price targets.
• Elanco exceeded quarterly expectations, reporting $0.34 in EPS versus a $0.27 estimate and $1.37 billion in revenue, up 10.2% year over year. Company insiders also purchased more than 63,000 shares over the past three months.

State Street Corp grew its holdings in Elanco Animal Health Incorporated (NYSE:ELAN - Free Report) by 4.7% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 16,063,046 shares of the company's stock after purchasing an additional 726,567 shares during the quarter. State Street Corp owned approximately 3.22% of Elanco Animal Health worth $395,312,000 at the end of the most recent reporting period.

Several other institutional investors also recently modified their holdings of the business. Anchor Investment Management LLC acquired a new position in Elanco Animal Health in the second quarter valued at approximately $29,000. Talon Private Wealth LLC acquired a new position in shares of Elanco Animal Health in the 2nd quarter valued at $780,000. The Manufacturers Life Insurance Company boosted its position in shares of Elanco Animal Health by 34.1% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 8,355,772 shares of the company's stock worth $205,636,000 after purchasing an additional 2,126,727 shares during the last quarter. Tidal Investments LLC boosted its position in shares of Elanco Animal Health by 1.4% in the 2nd quarter. Tidal Investments LLC now owns 317,878 shares of the company's stock worth $7,823,000 after purchasing an additional 4,349 shares during the last quarter. Finally, Integrated Wealth Concepts LLC acquired a new stake in shares of Elanco Animal Health during the second quarter worth $35,000. Institutional investors and hedge funds own 97.48% of the company's stock.

Wall Street Analyst Weigh In

A number of research firms recently commented on ELAN. KeyCorp upped their price objective on Elanco Animal Health from $29.00 to $30.00 and gave the company an "overweight" rating in a report on Thursday, August 6th. Weiss Ratings upgraded Elanco Animal Health from a "sell (d)" rating to a "sell (d+)" rating in a research report on Friday, September 4th. UBS Group boosted their target price on Elanco Animal Health from $31.00 to $33.00 and gave the stock a "buy" rating in a research report on Thursday, August 6th. TD Cowen upped their price target on Elanco Animal Health from $31.00 to $32.00 and gave the company a "buy" rating in a research note on Thursday, June 18th. Finally, Piper Sandler reiterated an "overweight" rating on shares of Elanco Animal Health in a research report on Monday, June 29th. One research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $29.70.

Elanco Animal Health Stock Performance

Shares of Elanco Animal Health stock opened at $22.61 on Thursday. The stock's fifty day simple moving average is $24.18 and its 200 day simple moving average is $23.76. The company has a current ratio of 2.05, a quick ratio of 1.10 and a debt-to-equity ratio of 0.58. The company has a market capitalization of $11.30 billion, a PE ratio of -55.16, a PEG ratio of 1.63 and a beta of 1.68. Elanco Animal Health Incorporated has a 12 month low of $18.48 and a 12 month high of $27.98.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last posted its earnings results on Wednesday, August 5th. The company reported $0.34 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.27 by $0.07. Elanco Animal Health had a positive return on equity of 8.13% and a negative net margin of 3.96%.The firm had revenue of $1.37 billion during the quarter, compared to analysts' expectations of $1.31 billion. During the same period in the previous year, the firm earned $0.26 earnings per share. The company's revenue was up 10.2% on a year-over-year basis. Elanco Animal Health has set its Q3 2026 guidance at 0.190-0.220 EPS and its FY 2026 guidance at 1.100-1.160 EPS. On average, research analysts predict that Elanco Animal Health Incorporated will post 1.13 EPS for the current year.

Insider Buying and Selling

In related news, Director Lawrence Kurzius acquired 40,000 shares of the company's stock in a transaction that occurred on Thursday, August 20th. The shares were acquired at an average cost of $23.40 per share, for a total transaction of $936,000.00. Following the completion of the acquisition, the director directly owned 188,647 shares in the company, valued at approximately $4,414,339.80. The trade was a 26.91% increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CFO Robert M. Vanhimbergen acquired 4,200 shares of the business's stock in a transaction that occurred on Friday, August 7th. The stock was bought at an average cost of $23.08 per share, for a total transaction of $96,936.00. Following the completion of the transaction, the chief financial officer directly owned 137,516 shares in the company, valued at $3,173,869.28. This represents a 3.15% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Over the last three months, insiders have acquired 63,198 shares of company stock valued at $1,473,109. 1.14% of the stock is owned by corporate insiders.

About Elanco Animal Health

Elanco Animal Health Incorporated NYSE: ELAN is a global animal health company that develops, manufactures and markets products for pets and food-producing animals. Its portfolio is designed to help prevent and treat disease, control parasites, improve animal well-being and support productivity in livestock and aquaculture.

The company's products include vaccines, parasiticides, antibiotics, animal health pharmaceuticals and nutritional supplements. Its companion animal portfolio serves dogs and cats, while its livestock business provides products for cattle, poultry, swine and aquaculture operations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.